Showing 2141-2150 of 5643 results for "".
- Ripple Therapeutics Partners with AbbVie to Develop Intracameral Implant for Glaucomahttps://modernod.com/news/ripple-therapeutics-partners-with-abbvie-to-develop-intracameral-implant-for-glaucoma/2482444/Ripple Therapeutics announced a collaboration and option-to-license agreement with AbbVie to advance the development of RTC-620, a fully biodegradable, sustained-release intracameral implant designed to reduce IOP in patients suffering from open-angle glaucoma (OAG) or ocular hypertensi
- Atsena Therapeutics Granted FDA Orphan Drug Designation for Gene Therapy Targeting XLRShttps://modernod.com/news/atsena-therapeutics-granted-fda-orphan-drug-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482443/The FDA has granted Orphan Drug Designation to Atsena Therapeutics' product candidate, ATSN-201, which is designed for the treatment of X-linked retinoschisis (XLRS). This gene therapy utilizes the company’s AAV.SPR capsid technology, which enables targeted gene expression in the p
- Nanoscope Plans Phase 3 Trial of MCO-010 to Treat Stargardt Macular Degenerationhttps://modernod.com/news/nanoscope-plans-phase-3-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2482440/Nanoscope Therapeutics announced the completion of an End-of-phase 2 (EOP2) meeting with the FDA for its clinical program evaluating MCO-010 for the treatment of severe vision loss caused by Stargardt macular degeneration (SMD), supporting advancement of MCO-010 to a phase 3 registrational trial.
- Oculus Debuts Dual Testing Functionality on Easyfield VR for Enhanced Visual Field Assessmenthttps://modernod.com/news/oculus-debuts-dual-testing-functionality-on-easyfield-vr-for-enhanced-visual-field-assessment/2482416/Oculus has announced the debut of dual testing functionality on its Oculus Easyfield VR, which allows for both Frequency Doubling Perimetry (FDP) and Standard Automated Perimetry (SAP). The integration of Frequency Doubling Perimetry into the Easyfield VR allows for the potent
- Rayner Launches First AI-Designed Spiral IOL, the RayOne Galaxyhttps://modernod.com/news/rayner-announces-launch-of-rayone-galaxy-first-ai-designed-spiral-iol/2482411/Rayner announced its plans to launch the RayOne Galaxy and Galaxy Toric, which the company is calling the world’s first IOL designed with the aid of artificial intelligence. The IOLs will be unveiled at the European Society of Cataract and Refractive Surgeons (
- Ocutech Announces Release of SideSight Ultrasonic Sensor Device for Homonymous Hemianopiahttps://modernod.com/news/ocutech-announces-limited-release-of-sidesight-ultrasonic-sensor-device-for-homonymous-hemianopia/2482405/Ocutech announced the limited first release of its new ultrasonic sensor device, the SideSight. Developed in collaboration with experts in electrical, software, and mechanical engineering, Ocutech says the SideSight is designed to assist individuals who have experienced loss of side vision, a con
- Opus Genetics Receives FDA Rare Pediatric Disease Designation for Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-receives-fda-rare-pediatric-disease-designation-for-gene-therapy-opgx-lca5/2482403/Opus Genetics announced that the FDA has granted rare pediatric disease (RPD) designation for its ocular gene therapy, OPGx-LCA5. This therapy is designed to treat patients with Leber congenital amaurosis (LCA) type 5, a rare inherited retinal disease caused by biallelic mutations in th
- Atsena Therapeutics Secures FDA Rare Pediatric Disease Designation for XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-fda-rare-pediatric-disease-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482398/The FDA has granted rare pediatric disease (RPD) designation for Atsena Therapeutics' gene therapy pruduct candidate ATSN-201, which is being examined to treat X-linked retinoschisis (XLRS). XLRS is a rare genetic disorder that leads to vision loss primarily in males.
- Contact Lens Institute Opens Nominations for Second Annual Culture Awardshttps://modernod.com/news/contact-lens-institute-opens-nominations-for-second-annual-culture-awards/2482394/The Contact Lens Institute (CLI) has announced that nominations for the second annual CLI Culture Awards are now open, with submissions being accepted through October 1, 2024. This program aims to recognize eye care professionals who are committed to fostering a positive culture around contact le
- Study Examines Effectiveness of Injection of Retinal Progenitor Cells (RPCs) in Treating Photoreceptor Degenerationhttps://modernod.com/news/study-examines-effectiveness-of-injection-of-retinal-progenitor-cells-rpcs-in-treating-photoreceptor-degeneration/2482387/A preclinical study demonstrates the effectiveness of intravitreal injection of retinal progenitor cells (RPCs) (jCell) in treating photoreceptor degeneration. The research, from the Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center at the University of